What Oregon's Anesthetic Ban Reveals About a Much Bigger Conversation in PMU
- Michelle Rukny
- No Comments
Table of Contents
In March 2026, the Oregon Health Authority's Health Licensing Office issued a practice clarification that sent shockwaves through the permanent makeup community.
The clarification stated that the administration of topical anesthesia to a client by a licensed tattoo artist is not within their scope of practice, and that administering drugs to other people may constitute the practice of medicine. OPB.
The practice clarification applies under no circumstance, meaning tattoo artists across Oregon cannot apply topical anesthetics of any kind. This includes over-the-counter products like Bactine spray and standard numbing creams that have been commonplace in PMU studios for years.
The reaction from the industry was immediate. Cosmetic tattoo artist Heather Parish, who offers permanent makeup services and education in Beaverton, called the clarification a surprise and said it would devastate the entire permanent makeup industry. Artists scrambled to reschedule appointments, and many expressed concern that clients would simply cross state lines to receive services elsewhere. OPB.
It is worth noting that this is technically a clarification of existing rules rather than new legislation, meaning the restrictions were already in effect. Oregon did not recently ban anesthetics outright. The Health Licensing Office simply made explicit what they interpreted the existing scope of practice to prohibit. That distinction matters, and it is one the industry is actively pushing back on. Reformoregontattooing.
Oregon is now one of only two states in the U.S. that bans all topical anesthetics for tattoo purposes, joining Michigan, which issued a similar ruling last year.
Why This Matters for the PMU Industry Nationally
Oregon is not the AAM’s backyard, but what happens there is a preview of what can happen anywhere when the regulatory infrastructure governing permanent makeup is not thoughtfully built. When PMU artists operate under the same licensing framework as general tattoo artists, they are subject to the same scope of practice restrictions, even when the nature of their work is fundamentally different.
This is precisely why the AAM has long advocated for permanent makeup to be recognized as a distinct discipline requiring its own regulatory framework. The Oregon situation is a concrete example of what it looks like when that distinction is absent. PMU artists rely on topical anesthetics as a standard part of their practice in a way that most body art tattooers do not, and a blanket restriction that treats both the same fails to account for that reality.
Under the Oregon clarification, clients may still self-administer topical anesthesia before their appointment, as that falls outside the board’s regulation of the artist. But this is not a workable solution for most PMU procedures, where proper application, timing, and secondary numbing during the procedure are part of delivering a safe and effective service.
But Here Is What the Industry Also Needs to Acknowledge
The Oregon situation is worth pushing back on procedurally and regulatorily. At the same time, the conversation it has sparked gives the PMU community an opportunity to be honest about something that has not always been handled well: anesthetic misuse is a real problem, and it has caused real harm.
The Oregon Health Authority cited two specific incidents involving topical anesthetics used during cosmetic tattoo appointments that resulted in clients being hospitalized for eye irritations. One incident occurred in Albany in 2016, and the other in Bend in 2012. These incidents, now over a decade old, were part of the reasoning offered for the current clarification.
Those cases are not isolated. The medical literature and regulatory record contain documented instances of serious adverse events tied to improper anesthetic use in cosmetic procedures. A published case report in the National Institutes of Health database describes a 33-year-old woman who applied four tubes of a topical anesthetic gel containing lidocaine and epinephrine to her chest over several hours during a tattoo session, resulting in a racing heart rate, elevated blood pressure, headaches, chest pain, nausea, vomiting, and anxiety. She was admitted to the intensive care unit following the incident, with laboratory findings concerning severe lactic acidosis and a non-ST elevation myocardial infarction. nih.
This was not an isolated reckless act. It was the result of a product being applied without proper guidance, in excessive quantity, to a large surface area, over an extended period of time.
The Science of Topical Numbing: What Every PMU Artist Should Understand
Concentration matters.
The FDA advises consumers not to use OTC products with more than 4% lidocaine on the skin. Lidocaine concentrations higher than 4% increase the risk of systemic absorption, which can lead to lidocaine toxicity, with symptoms that may include dizziness, tremors, seizures, respiratory distress, or even cardiac arrest in severe cases. Many products marketed directly to tattoo artists and PMU practitioners contain concentrations well above this threshold. Healio.
Topical anesthetics work by temporarily blocking nerve signal transmission at the application site. Most products used in PMU contain lidocaine as the primary active ingredient, sometimes combined with epinephrine, prilocaine, or tetracaine. Understanding how these compounds behave in the body is not optional for a practitioner applying them to clients. It is part of the standard of care.
When high concentrations of lidocaine are applied in ways that increase absorption, dangerous side effects can occur, including irregular heartbeat, seizures, and breathing difficulties. The key phrase here is “in ways that increase absorption.” Several factors directly influence how much lidocaine enters systemic circulation, and a practitioner who does not understand these factors cannot properly manage the risk. Healio.
Surface area and application volume matter.
Applying a numbing agent over a small, localized area is very different from applying it across a broad region. The larger the surface area covered, the greater the potential for systemic absorption.
Broken or compromised skin matters.
Applying anesthetics directly to irritated or broken skin increases absorption significantly. In PMU, where the skin is being opened during the procedure, secondary numbing applied mid-service requires particular care. About Lawsuits.
Occlusion matters significantly.
Wrapping or covering treated skin with any type of material can increase the risk of serious adverse events. Plastic wrap application, which has been common in the industry for pre-numbing, increases absorption dramatically and should be used, if at all, only with a clear understanding of the risk and appropriate client screening. MedEsthetics.
Drug interactions matter.
Topical anesthetics can interact with other medications or supplements a person is taking. A proper intake and health history form is not a formality. It is a safety tool. Dermsquared.
What Responsible Anesthetic Use Looks Like
None of this means that topical anesthetics are inherently dangerous or that their use in PMU is inappropriate. Used correctly, within appropriate concentration limits, with proper intake screening, and by a practitioner who understands the pharmacology involved, they are a legitimate and valuable part of delivering a comfortable client experience.
What is not appropriate is treating them as a commodity, something to grab off a shelf, apply liberally, and think nothing more about. The FDA has been clear about the risks associated with high-concentration products, and the PMU industry has a responsibility to take that seriously rather than treating numbing as an afterthought.
Responsible anesthetic use in PMU includes using products within FDA-recommended concentration limits, conducting thorough health history intake to screen for contraindications and medication interactions, understanding the difference between pre-service and mid-service application and how the skin’s condition changes between the two, never applying to large surface areas without appropriate precaution, and never instructing clients to self-apply at high concentrations or under occlusion at home without proper guidance.
The Bigger Picture
The Oregon clarification is, at its core, a regulatory failure. It is what happens when the people making decisions about PMU practice standards do not fully understand what PMU practice involves. The answer to that is not silence. It is organized, informed advocacy from credentialed professionals who can demonstrate that this industry has the knowledge and the standards to manage these tools responsibly.
The AAM exists to build and uphold exactly that kind of credibility. Board certification is not just about recognizing skill. It is about demonstrating that a practitioner operates at a level of knowledge and professionalism that regulators can trust. The more PMU artists operate at that standard, the harder it becomes for regulatory bodies to paint the entire profession with the broad brush that Oregon just used.
What happened in Oregon should not be dismissed as someone else’s problem. It is a signal worth taking seriously, and the response to it should be both advocacy and accountability.
